Beatriz León Ruiz

Dr. Beatriz León Ruiz


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
BRBeatriz León Ruiz
Beatriz León Ruiz
ABAndre Ballesteros-Tato
Andre Ballesteros-Tato
It is estimated that more than 339 million people worldwide suffer from asthma. The leading cause of asthma development is the breakdown of immune tolerance to inhaled allergens, prompting the immune system's aberrant activation. During the early phase, also known as the sensitization phase, allergen-specific T cells are activated and become central players in orchestrating the subsequent development of allergic asthma following secondary exposure to the same allergens. It is well-established that allergen-specific T helper 2 (Th2) cells play central roles in developing allergic asthma. As such, 80% of children and 60% of adult asthma cases are linked to an unwarranted Th2 cell response against respiratory allergens. Thus, targeting essential components of Th2-type inflammation using neutralizing antibodies against key Th2 modulators has recently become an attractive option for asthmatic patients with moderate to severe symptoms. In addition to directly targeting Th2 mediators, allergen immunotherapy, also known as desensitization, is focused on redirecting the allergen-specific T cells response from a Th2-type profile to a tolerogenic one. This review highlights the current understanding of the heterogeneity of the Th2 cell compartment, their contribution to allergen-induced airway inflammation, and the therapies targeting the Th2 cell pathway in asthma. Further, we discuss available new leads for successful targeting pulmonary Th2 cell responses for future therapeutics.

1 February 2016 in Immunity
Verified
Journal Article
Closed access
ABAndré Ballesteros-Tato
André Ballesteros-Tato
TRTroy D. Randall
Troy D. Randall
FLFrances E. Lund
Frances E. Lund
RSRosanne Spolski
Rosanne Spolski
WLWarren J. Leonard
Warren J. Leonard
BRBeatriz León Ruiz
Beatriz León Ruiz

10 January 2023 in Frontiers in Allergy
Verified
Journal Article
Open access
BRBeatriz León Ruiz
Beatriz León Ruiz
Allergic diseases, including atopic dermatitis, allergic rhinitis, asthma, and food allergy, are caused by abnormal responses to relatively harmless foreign proteins called allergens found in pollen, fungal spores, house dust mites (HDM), animal dander, or certain foods. In particular, the activation of allergen-specific helper T cells towards a type 2 (Th2) phenotype during the first encounters with the allergen, also known as the sensitization phase, is the leading cause of the subsequent development of allergic disease. Infants and children are especially prone to developing Th2 cell responses after initial contact with allergens. But in addition, the rates of allergic sensitization and the development of allergic diseases among children are increasing in the industrialized world and have been associated with living in urban settings. Particularly for respiratory allergies, greater susceptibility to developing allergic Th2 cell responses has been shown in children living in urban environments containing low levels of microbial contaminants, principally bacterial endotoxins [lipopolysaccharide (LPS)], in the causative aeroallergens. This review highlights the current understanding of the factors that balance Th2 cell immunity to environmental allergens, with a particular focus on the determinants that program conventional dendritic cells (cDCs) toward or away from a Th2 stimulatory function. In this context, it discusses transcription factor-guided functional specialization of type-2 cDCs (cDC2s) and how the integration of signals derived from the environment drives this process. In addition, it analyzes observational and mechanistic studies supporting an essential role for innate sensing of microbial-derived products contained in aeroallergens in modulating allergic Th2 cell immune responses. Finally, this review examines whether hyporesponsiveness to microbial stimulation, particularly to LPS, is a risk factor for the induction of Th2 cell responses and allergic sensitization during infancy and early childhood and the potential factors that may affect early-age response to LPS and other environmental microbial components.

1 January 2019 in Immunity
Verified
Journal Article
Closed access
HBHolly Bachus
Holly Bachus
KKKamaljeet Kaur
Kamaljeet Kaur
APAmber M. Papillion
Amber M. Papillion
TMTatiana T. Marquez-Lago
Tatiana T. Marquez-Lago
ZYZhihong Yu
Zhihong Yu
BRBeatriz León Ruiz
Beatriz León Ruiz

12 April 2023 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
HBHolly Bachus
Holly Bachus
EMErin McLaughlin
Erin McLaughlin
CLCrystal Lewis
Crystal Lewis
APAmber M. Papillion
Amber M. Papillion
EBEtty N. Benveniste
Etty N. Benveniste
BRBeatriz León Ruiz
Beatriz León Ruiz
Defective interleukin-6 (IL-6) signaling has been associated with Th2 bias and elevated IgE levels. However, the underlying mechanism by which IL-6 prevents the development of Th2-driven diseases remains unknown. Using a model of house dust mite (HDM)-induced Th2 cell differentiation and allergic airway inflammation, we showed that IL-6 signaling in allergen-specific T cells was required to prevent Th2 cell differentiation and the subsequent IgE response and allergic inflammation. Th2 cell lineage commitment required strong sustained IL-2 signaling. We found that IL-6 turned off IL-2 signaling during early T-cell activation and thus inhibited Th2 priming. Mechanistically, IL-6-driven inhibition of IL-2 signaling in responding T cells was mediated by upregulation of Suppressor Of Cytokine Signaling 3 (SOCS3). This mechanism could be mimicked by pharmacological Janus Kinase-1 (JAK1) inhibition. Collectively, our results identify an unrecognized mechanism that prevents the development of unwanted Th2 cell responses and associated diseases and outline potential preventive interventions.

29 May 2017 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
BRBeatriz León Ruiz
Beatriz León Ruiz